--- title: "Eton Pharmaceuticals (ETON) news: offering" url: "https://aibio.space/companies/eton-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ETON offering news: Eton sells 583,334 shares at $12.00 in $7.0 million registered direct offering. Eton Pharmaceuticals, Inc. (NASDAQ: ETON), United States." --- ETON Eton Pharmaceuticals, Inc. NASDAQ · United States # Eton Pharmaceuticals (ETON) news ETON offering news Mergers · 2026-10-14 ## [Eton Pharmaceuticals pays $10.0 million upfront for US rights to Aquestive's Libervant](https://aibio.space/news/eton-pharmaceuticals-pays-10-0-million-upfront-us-rights-aquestives/) Milestones could add up to $47.5 million, plus royalties at a mid-teens percentage of net sales. The product has tentative FDA approval only, and Aquestive will be its exclusive manufacturer under a 20-year supply agreement. ## Latest Eton Pharmaceuticals news 1. 2026-08-05 Mergers [Eton Pharmaceuticals licenses ASN-001 from Auson for $3.0 million upfront](https://aibio.space/news/eton-pharmaceuticals-licenses-asn-001-auson-3-0-million-upfront/) Eton (Nasdaq: ETON) signed a license agreement for ASN-001, a late-stage infantile hemangioma gel. It owes milestone payments after FDA approval and tiered royalties of 10% to 15% on net sales. 2. 2025-01-03 Mergers [Eton Pharmaceuticals completes acquisition of Galzin from Teva for $7.0 million at closing](https://aibio.space/news/eton-pharmaceuticals-completes-acquisition-galzin-teva-7-0-million/) Eton bought the Wilson Disease treatment on December 31, 2024 for $7.0 million at closing plus $0.2 million for inventory. It will also pay Teva a 10% royalty on U.S. net sales through the tenth anniversary of its first U.S. sale. 3. 2024-12-12 Financings [Eton sells 583,334 shares at $12.00 in $7.0 million registered direct offering](https://aibio.space/news/eton-sells-583-334-shares-12-00-7-0-million-registered-direct-offering/) The shares went to one institutional investor, and the prospectus says no placement agent or underwriter was involved. The prospectus puts the immediate dilution to the buyer at $11.35 per share. ## Eton Pharmaceuticals at a glance - **Ticker**: ETON - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $26.8 million ### Related companies - [Legend Biotech](https://aibio.space/companies/legend-biotech/) NASDAQ: LEGN - [Alzamend Neuro](https://aibio.space/companies/alzamend-neuro/) NASDAQ: ALZN - [Arbutus Biopharma](https://aibio.space/companies/arbutus-biopharma/) NASDAQ: ABUS - [TRex Bio](https://aibio.space/companies/trex-bio/) NASDAQ: TRXB - [Obsidian Therapeutics](https://aibio.space/companies/obsidian-therapeutics/) NASDAQ: OBX - [Actuate Therapeutics](https://aibio.space/companies/actuate-therapeutics/) NASDAQ: ACTU - [ANTHERA PHARMACEUTICALS INC](https://aibio.space/companies/anthera-pharmaceuticals/) OTC: ANTH - [Cellectar Biosciences](https://aibio.space/companies/cellectar-biosciences/) NASDAQ: CLRB ### Also on NASDAQ - [Lucid Diagnostics](https://aibio.space/companies/lucid-diagnostics/) LUCD - [Hemab Therapeutics Holdings](https://aibio.space/companies/hemab-therapeutics/) COAG - [ABVC BioPharma](https://aibio.space/companies/abvc-biopharma/) ABVC - [Pulmonx](https://aibio.space/companies/pulmonx/) LUNG - [Larimar Therapeutics](https://aibio.space/companies/larimar-therapeutics/) LRMR - [Outlook Therapeutics](https://aibio.space/companies/outlook-therapeutics/) OTLK ## What Eton Pharmaceuticals does Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. It lists eight commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, PKU GOLIKE, carglumic acid, betaine anhydrous and nitisinone. INCRELEX is a biologic approved by the FDA in August 2005 for children with severe primary insulin-like growth factor 1 deficiency, and it is approved in 40 territories. ALKINDI SPRINKLE, approved by the FDA in September 2020, is a granule hydrocortisone formulation for replacement therapy in children under 17 with adrenocortical insufficiency. KHINDIVI, approved by the FDA in May 2025, is an oral hydrocortisone solution for pediatric patients five years of age and older. GALZIN is FDA-approved as a maintenance treatment for patients with Wilson disease who were initially treated with a chelating agent, and the company offers it through its Eton Cares patient support program. PKU GOLIKE is a medical formula for the dietary management of phenylketonuria under medical supervision. The company has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and the ZENEO hydrocortisone autoinjector. | Product or program | What it is | Stage | |---|---|---| | INCRELEX | Biologic for children with severe primary IGF-1 deficiency | approved by the FDA in August 2005 | | ALKINDI SPRINKLE | Granule hydrocortisone for adrenocortical insufficiency in children under 17 | approved by the FDA in September 2020 | | KHINDIVI | Oral hydrocortisone solution for pediatric adrenocortical insufficiency | approved by the FDA in May 2025 | | GALZIN | Maintenance treatment for Wilson disease after initial chelation | FDA-approved | | PKU GOLIKE | Medical formula for dietary management of phenylketonuria | commercial | | ZENEO hydrocortisone autoinjector | Hydrocortisone autoinjector in late-stage development | late-stage development | Summarised from the company's [10-K filed Mar 19, 2026](https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm). ## Eton Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$80.0 million](https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/) | [$39.0 million](https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/) | | Research and development | [$7.8 million](https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/) | [$3.3 million](https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/) | | Net income (loss) | [-$4.6 million](https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/) | [-$3.8 million](https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/) | | Cash from operations | [$10.5 million](https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/) | [$969,000](https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/) | | Cash and equivalents | [$25.9 million](https://www.sec.gov/Archives/edgar/data/1710340/000143774926027684/) | [$14.9 million](https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $26.8 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Eton Pharmaceuticals Has Eton Pharmaceuticals raised money recently? Our latest story on this, dated Dec 12, 2024: "Eton sells 583,334 shares at $12.00 in $7.0 million registered direct offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/eton-sells-583-334-shares-12-00-7-0-million-registered-direct-offering/). What is the ticker symbol of Eton Pharmaceuticals? Eton Pharmaceuticals, Inc. trades under the ticker ETON on NASDAQ. Where is Eton Pharmaceuticals listed? Eton Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of Eton Pharmaceuticals? The SEC Central Index Key (CIK) for Eton Pharmaceuticals, Inc. is 1710340. Its filings are on SEC EDGAR. How many shares does Eton Pharmaceuticals have outstanding? 28,583,135 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Eton Pharmaceuticals listed under? Our directory records Eton Pharmaceuticals, Inc. under United States. What does Eton Pharmaceuticals do? Our directory classifies Eton Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Eton Pharmaceuticals? The ISIN recorded for Eton Pharmaceuticals, Inc. is US29772L1089. Does aibio.space cover Eton Pharmaceuticals? aibio.space lists Eton Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Eton Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Eton Pharmaceuticals develop? Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. It lists eight commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, PKU GOLIKE, carglumic acid, betaine anhydrous and nitisinone. What is INCRELEX from Eton Pharmaceuticals? INCRELEX: Biologic for children with severe primary IGF-1 deficiency Stage: approved by the FDA in August 2005. What is ALKINDI SPRINKLE from Eton Pharmaceuticals? ALKINDI SPRINKLE: Granule hydrocortisone for adrenocortical insufficiency in children under 17 Stage: approved by the FDA in September 2020. What was Eton Pharmaceuticals's revenue last year? $80.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Eton Pharmaceuticals profitable? Eton Pharmaceuticals, Inc. reported a net loss of $4.6 million for the fiscal year ended Dec 31, 2025, and generated $10.5 million of cash from operations, per its annual report to the SEC. ## Investor discussion: Eton Pharmaceuticals Members talk about Eton Pharmaceuticals (ETON). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Eton Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-10-14 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1710340/000143774926032600/eton20261013_8k.htm) 2. 2026-08-05 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1710340/000143774926025781/ex_997306.htm) 3. 2026-05-19 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1710340/000143774926017799/eton20260518_8k.htm) 4. 2026-03-02 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1710340/000143774926006209/eton20260223c_8k.htm) 5. 2025-06-20 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1710340/000143774925020916/eton20250613_8k.htm) 6. 2025-01-03 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1710340/000143774925000109/eton20241219_8k.htm) 7. 2024-12-20 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1710340/000143774924038020/eton20241215_8k.htm) 8. 2024-12-12 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1710340/000143774924037363/eton20241212_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ETON on TradingView](https://www.tradingview.com/symbols/NASDAQ-ETON/). ## SEC filings and registration - **SEC name**: Eton Pharmaceuticals, Inc. - **CIK**: 1710340 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ETON (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 21925 W. FIELD PARKWAY, DEER PARK, IL, 60010-7278 - **Phone**: (847) 787-7361 - **Shares outstanding**: 28,583,135 as of 2026-08-11 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774926032600/eton20261013_8k.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774926031281/eton20260923c_8k.htm) filed 2026-09-28 - [10-Q](https://www.sec.gov/Archives/edgar/data/1710340/000143774926027684/eton20260630_10q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774926027672/eton20260608_8k.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774926025781/eton20260803_8k.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774926025506/eton20260731_8k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774926024746/eton20260723_8k.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774926020005/eton20260409_8k.htm) filed 2026-06-09 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001710340), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Eton Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ETON, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Eton Pharmaceuticals, Inc. - **Ticker**: ETON - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US29772L1089 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ETON/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/eton-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Eton Pharmaceuticals (ETON) news: offering", 2026-10-31, https://aibio.space/companies/eton-pharmaceuticals/